Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Semaglutide (a GLP-1R monoagonist) achieved mean weight reductions of approximately 1517% in the STEP clinical trial programme (STEP-1, NEJM 2021)
These include: Nausea the most frequently reported adverse effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive) Abdominal discomfort or pain These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or when the dose is increased
We ship with cold packs, but we cannot control how quickly researchers transfer vials to freezers, whether refrigerators maintain stable temperatures, or whether reconstituted vials are labeled with dates
Sources: When taking BPC-157, it's important to follow recommended dosing practices for safety and effectiveness
Blood here doesnt stay the same
Can GLP-1 medications reduce milk supply
